Want to see MEDS full AI Analyst Report?
DataMeds AI (MEDS) AI Stock Analysis
DataMeds AI
(NASDAQ:MEDS)
The score is driven primarily by severe financial weakness, including negative equity, persistent cash burn, collapsing revenue, and widening losses. Bearish technical trends and loss-based valuation further weigh on the result. Recent corporate developments provide some potential strategic upside but are insufficient to offset the company’s financial and dilution risks.
DataMeds AI (MEDS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $8.63M
- Dividend Yield
- ―
- Average Volume (3M)
- 6.51M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 0.10
- Revenue Growth
- -78.16%
- EPS Growth
- -15.07%
- Country
- US
- Employees
- 31
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
DataMeds AI Business Overview & Revenue Model
Company Description
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRxâ„¢ and blockchain-enabled...
DataMeds AI Financial Statement Overview
Summary
Severely distressed financial condition: revenue has collapsed, losses and margins have deteriorated sharply, equity is deeply negative, debt is high, and operating and free cash flow remain materially negative.
Income Statement
5Very NegativeBalance Sheet
8Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.02M | 23.34M | 18.13M | 0 | 32.78M |
| Gross Profit | -10.04M | -9.64M | 1.77M | 0 | 5.75M |
| EBITDA | -56.41M | -93.48M | -4.91M | -2.88M | -369.03K |
| Net Income | -88.28M | -101.27M | -6.86M | -2.90M | -2.74M |
Balance Sheet | |||||
| Total Assets | 32.76M | 30.46M | 57.33M | 338.36K | 0 |
| Cash, Cash Equivalents and Short-Term Investments | 2.46M | 42.57K | 1.03M | 1,364 | 0 |
| Total Debt | 32.62M | 24.77M | 25.11M | 700.00K | 0 |
| Total Liabilities | 52.26M | 42.91M | 50.60M | 3.24M | 5,250 |
| Stockholders Equity | -19.50M | -12.45M | 6.73M | -2.90M | -5,250 |
Cash Flow | |||||
| Free Cash Flow | -13.59M | -10.86M | -1.60M | -349.14K | 0 |
| Operating Cash Flow | -13.74M | -10.86M | -1.22M | -349.14K | 0 |
| Investing Cash Flow | -923.70K | -881.53K | 469.07K | 0 | 0 |
| Financing Cash Flow | 16.70M | 10.75M | 1.78M | 350.50K | 0 |
DataMeds AI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MEDS, the sentiment is Negative. The current price of 1.92 is below the 20-day moving average (MA) of 2.66, below the 50-day MA of 2.47, and below the 200-day MA of 5.86, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 38.93 is Neutral, neither overbought nor oversold. The STOCH value of 10.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MEDS.
DataMeds AI Risk Analysis
DataMeds AI disclosed 64 risk factors in its most recent earnings report. DataMeds AI reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksDataMeds AI Peers Comparison
Overall Rating
MCK74Outperform
COR71Outperform
HSIC55Neutral
ACH42Neutral- MEDS40.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| MCK | 74Outperform | $115.96B | 26.50 | -194.39% | 0.34% | 8.84% | 48.98% |
| COR | 71Outperform | $63.13B | 24.47 | 106.43% | 0.73% | 5.09% | 38.10% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HSIC | 55Neutral | $9.46B | 24.53 | 12.37% | ― | 6.49% | 10.41% |
| ACH | 42Neutral | $19.56M | -0.06 | 63.40% | ― | -69.68% | 74.88% |
| MEDS | 41Neutral | $8.63M | -0.04 | 877.58% | ― | -78.16% | -15.07% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MEDS | Datameds Ai, Inc. | 1.92 | -31.49 | -94.25% | |
| COR | Cencora, Inc. | 330.84 | -7.51 | -2.22% | |
| HSIC | Henry Schein | 84.88 | 20.24 | 31.31% | |
| MCK | McKesson Corporation | 994.58 | 177.51 | 21.72% | |
| ACH | Accendra Health Inc | 0.25 | -3.20 | -92.64% | |
| HKPD | Hong Kong Pharma Digital Technology Holdings Ltd. | 1.98 | -23.22 | -92.14% |
DataMeds AI Corporate Events
DataMeds AI Pursues Transformative Telehealth IP Acquisition
PositiveOn October 21–22, 2026, DataMEDS AI entered into a non-binding Second Amended and Restated Letter of Intent with Datavault AI, EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors, Tollo Health and REBOOT Health AI to license...
DataMeds AI Regains Nasdaq Equity Compliance Status
PositiveOn October 20, 2026, DataMeds AI, Inc., a Tampa-based health technology and pharmacy services company trading on Nasdaq under MEDS, reported that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) governing minimum stockholders’ equ...
DataMeds AI Licenses REBOOT Platform, Issues Equity
PositiveOn October 13, 2026, DataMeds AI, Inc. entered into an Intellectual Property License and Product and Services Agreement with REBOOT Health AI, Inc., securing an exclusive U.S. license, within a defined field of use, to REBOOT’s patents and AI p...
DataMeds AI Restructures Equity and Forms Licensing Partnership
PositiveAs of October 13, 2026, DataMEDS AI reported stockholders’ equity above $2.5 million following a series of legal and strategic transactions. The company settled long-running disputes tied to a 2023 Membership Interest Purchase Agreement by payi...
DataMeds AI Settles Litigation, Strengthens Balance Sheet
PositiveOn September 11, 2026, DataMEDS AI, Inc. entered into a settlement agreement with several parties, including former counterparties to a Membership Interest Purchase Agreement dated May 11, 2023. The agreement follows reciprocal lawsuits in Florida an...
DataMeds AI Acquires Helomics to Expand Cancer Platform
PositiveOn September 11, 2026, DataMEDS AI entered a stock purchase agreement to acquire all outstanding shares of Helomics Corporation from Axe Compute Inc., paying with 636,328 DataMEDS common shares and a $1,363,672 convertible promissory note that mature...
DataMeds AI Announces Token-Based Shareholder Distribution Plan
NeutralDatavault AI Inc. plans a voluntary one-time distribution of Dream Bowl 2026 Meme Coin tokens to record holders of DataMEDS AI common stock as of August 7, 2026, with fifty tokens allocated per share. The payment is scheduled to begin on September 9,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 26, 2026